Model‐based treatment optimization of a novel VEGFR inhibitor - Keizer, Ron J.; Gupta, Anubha; Shumaker, Robert; Beijnen, Jos H.; Schellens, Jan H. M.; Huitema, Alwin D. R. (British journal of clinical pharmacology, 2012)
Keywords: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - adverse effects; Angiogenesis Inhibitors - pharmacokinetics; Antihypertensive Agents - therapeutic use; Arterial hypertension. Arterial hypotension; Biological and medical sciences; Blood and lymphatic vessels; Blood Pressure - drug effects; Cardiology. Vascular system; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Computer Simulation; Drug Administration Schedule; Female; Humans; hypertension; Hypertension - chemically induced; Hypertension - drug therapy; Hypertension - physiopathology; lenvatinib; Male; Markov Chains; Medical sciences; Middle Aged; modelling and simulation; Models, Biological; Neoplasms - drug therapy; Neoplasms - enzymology; Nephrology. Urinary tract diseases; oncology; pharmacodynamics; Pharmacokinetic Dynamic Relationships; Pharmacology. Drug treatments; Phenylurea Compounds - administration & dosage; Phenylurea Compounds - adverse effects; Phenylurea Compounds - pharmacokinetics; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - pharmacokinetics; proteinuria; Proteinuria - chemically induced; Quinolines - administration & dosage; Quinolines - adverse effects; Quinolines - pharmacokinetics; Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors; Receptors, Vascular Endothelial Growth Factor - metabolism; Research Design; Treatment Outcome; Urinary system involvement in other diseases. Miscellaneous; Urinary tract. Prostate gland; Hypertension; Pharmacodynamics; Urinary system disease; lenvatinib; Cardiovascular disease; Malignant tumor; Biological activity; Optimization; oncology; Vascular endothelium growth factor receptor; Cancerology; Treatment; Simulation; Inhibitor; Models; modelling and simulation; Cancer; Proteinuria